Literature DB >> 11258212

Clinical practice guidelines for the care and treatment of breast cancer: adjuvant systemic therapy for node-positive breast cancer (summary of the 2001 update). The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer.

M Levine1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11258212      PMCID： PMC80819     

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  5 in total

1.  Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

Authors: 
Journal:  Lancet       Date:  1998-05-16       Impact factor: 79.321

Review 2.  Adjuvant systemic therapy for women with node-positive breast cancer. The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer.

Authors: 
Journal:  CMAJ       Date:  1998-02-10       Impact factor: 8.262

3.  Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study.

Authors:  J Bergh; T Wiklund; B Erikstein; E Lidbrink; H Lindman; P Malmström; P Kellokumpu-Lehtinen; N O Bengtsson; G Söderlund; G Anker; E Wist; S Ottosson; E Salminen; P Ljungman; H Holte; J Nilsson; C Blomqvist; N Wilking
Journal:  Lancet       Date:  2000-10-21       Impact factor: 79.321

4.  Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group.

Authors:  M N Levine; V H Bramwell; K I Pritchard; B D Norris; L E Shepherd; H Abu-Zahra; B Findlay; D Warr; D Bowman; J Myles; A Arnold; T Vandenberg; R MacKenzie; J Robert; J Ottaway; M Burnell; C K Williams; D Tu
Journal:  J Clin Oncol       Date:  1998-08       Impact factor: 44.544

5.  Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

Authors: 
Journal:  Lancet       Date:  1998-09-19       Impact factor: 79.321
  5 in total
  8 in total

1.  Chemotherapy for older women with node-positive breast cancer.

Authors:  D Ginsburg
Journal:  CMAJ       Date:  2001-09-04       Impact factor: 8.262

Review 2.  Tamoxifen for breast cancer prevention: safety warning.

Authors:  Eric Wooltorton
Journal:  CMAJ       Date:  2002-08-20       Impact factor: 8.262

3.  Increased risk of locoregional recurrence for women with T1-2N0 triple-negative breast cancer treated with modified radical mastectomy without adjuvant radiation therapy compared with breast-conserving therapy.

Authors:  Bassam S Abdulkarim; Julie Cuartero; John Hanson; Jean Deschênes; David Lesniak; Siham Sabri
Journal:  J Clin Oncol       Date:  2011-06-13       Impact factor: 44.544

4.  Evaluating the efficacy of current clinical practice of adjuvant chemotherapy in postmenopausal women with early-stage, estrogen or progesterone receptor-positive, one-to-three positive axillary lymph node, breast cancer.

Authors:  M B Hannouf; M Brackstone; B Xie; G S Zaric
Journal:  Curr Oncol       Date:  2012-10       Impact factor: 3.677

5.  Cost effectiveness of a 21-gene recurrence score assay versus Canadian clinical practice in post-menopausal women with early-stage estrogen or progesterone-receptor-positive, axillary lymph-node positive breast cancer.

Authors:  Malek B Hannouf; Bin Xie; Muriel Brackstone; Gregory S Zaric
Journal:  Pharmacoeconomics       Date:  2014-02       Impact factor: 4.981

6.  Clinical practice guidelines for the care and treatment of breast cancer: 16. Locoregional post-mastectomy radiotherapy.

Authors:  Pauline T Truong; Ivo A Olivotto; Timothy J Whelan; Mark Levine
Journal:  CMAJ       Date:  2004-04-13       Impact factor: 8.262

7.  Elapsed time from breast cancer detection to first adjuvant therapy in a Canadian province, 1999-2000.

Authors:  Daniel Rayson; Darrell Chiasson; Ron Dewar
Journal:  CMAJ       Date:  2004-03-16       Impact factor: 8.262

Review 8.  The role of aromatase inhibitors in early breast cancer.

Authors:  Cathie T Chung; Robert W Carlson
Journal:  Curr Treat Options Oncol       Date:  2003-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.